Trial intelligence / Profile preview

Asciminib plus imatinib versus continued imatinib versus switch to nilotinib in CML-CP without deep molecular response

2018-001594-24Phase 2Active

Sponsor

Novartis

Start

Jul 2018

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1